Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Effectiveness of Ivermectin-Based Multidrug Therapy in Severe Hypoxic Ambulatory COVID-19 Patients

Sabine Hazan, Sonya Dave, Anoja W. Gunaratne, Sibasish Dolai, Robert L Clancy, Peter A. McCullough, Thomas J. Borody
doi: https://doi.org/10.1101/2021.07.06.21259924
Sabine Hazan
1ProgenaBiome, LLC, 1845 Knoll Dr., Ventura, CA, USA, 93003
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: drhazan@progenabiome.com
Sonya Dave
2Microbiome Research, 1845 Knoll Dr., Ventura, CA, USA, 93003
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anoja W. Gunaratne
3Centre for Digestive Diseases, 229 Great North Road, Five Dock, NSW, Australia, 2046
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sibasish Dolai
3Centre for Digestive Diseases, 229 Great North Road, Five Dock, NSW, Australia, 2046
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert L Clancy
3Centre for Digestive Diseases, 229 Great North Road, Five Dock, NSW, Australia, 2046
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter A. McCullough
4Texas A & M College of Medicine, Baylor Dallas Campus, Dallas TX, USA 75226
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas J. Borody
3Centre for Digestive Diseases, 229 Great North Road, Five Dock, NSW, Australia, 2046
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20+ RCTs. Having developed combination therapies for Helicobacter pylori, we tested various COVID-19 combinations and describe the most effective. In 24 consecutive COVID-19 subjects with high risk features, hypoxia and untreated moderate-severe symptoms averaging 9 days, we trialed this novel combination comprising ivermectin, doxycycline, zinc, and Vitamins D and C. It was highly effective. All subjects resolved symptoms in 11 days on average, and oxygen saturation improved in 24hrs (87.4% to 93.1%, p=0.001). Hospitalizations and deaths were significantly fewer (p<0.002 or 0.05, respectively) than in background-matched controls from the CDC database. Triple combination therapy is safe and effective even in moderate-severe patients with hypoxia treated in the outpatient setting.

Trial Registration N/A, see methods.

Competing Interest Statement

Competing interests: TJB and SH have corporate affiliation to ProgenaBiome, LLC and Topelia Therapeutics. S Dave has corporate affiliation to McKesson Specialty Health and North End Advisory, LLC. S Dolai has corporate affiliation to Topelia Therapeutics and Axent Medical. AWG has corporate affiliation to Topelia Therapeutics. RC and PAM have no disclosures. This study was funded and carried out by ProgenaBiome, LLC and Topelia Therapeutics. SH and TJB have patents relevant to the study.

Clinical Trial

NCT04949230

Funding Statement

This study was funded by ProgenaBiome, LLC.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by E&I Review Services (https://www.eandireview.com/) as study # 210006

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding: This study was funded by ProgenaBiome, LLC.

  • The authors state that they have obtained appropriate institutional review board approval and have followed principles of the Declaration of Helsinki for all human experimental investigations. Informed consent has been obtained from the participants involved.

  • Data-sharing: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Data Availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

  • List of abbreviations

    χ2
    test (Chi-Square Test)
    CDC
    (Center for Disease Control)
    CI
    (Confidence Interval)
    COVID-19
    (Coronavirus, SARS-COV-2)
    Hrs.
    (Hours)
    HAZDpaC
    (Hydroxychloroquine,Azithromycin,Vit D, Zinc Pack)
    H. pylori
    (Helicobacter pylori)
    ICT
    (Ivermectin Combination Therapy)
    PMH
    (Past Medical History)
    pt
    (point)
    pts
    (points)
    SEM
    (Standard Error of Mean)
    SOB
    (Shortness of breath)
    SpO2
    (Percent Saturation Peripheral Oxygen)
    temp
    (Body temperature in 0F)
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
    Back to top
    PreviousNext
    Posted July 07, 2021.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Effectiveness of Ivermectin-Based Multidrug Therapy in Severe Hypoxic Ambulatory COVID-19 Patients
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Effectiveness of Ivermectin-Based Multidrug Therapy in Severe Hypoxic Ambulatory COVID-19 Patients
    Sabine Hazan, Sonya Dave, Anoja W. Gunaratne, Sibasish Dolai, Robert L Clancy, Peter A. McCullough, Thomas J. Borody
    medRxiv 2021.07.06.21259924; doi: https://doi.org/10.1101/2021.07.06.21259924
    Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
    Citation Tools
    Effectiveness of Ivermectin-Based Multidrug Therapy in Severe Hypoxic Ambulatory COVID-19 Patients
    Sabine Hazan, Sonya Dave, Anoja W. Gunaratne, Sibasish Dolai, Robert L Clancy, Peter A. McCullough, Thomas J. Borody
    medRxiv 2021.07.06.21259924; doi: https://doi.org/10.1101/2021.07.06.21259924

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Infectious Diseases (except HIV/AIDS)
    Subject Areas
    All Articles
    • Addiction Medicine (174)
    • Allergy and Immunology (419)
    • Anesthesia (97)
    • Cardiovascular Medicine (894)
    • Dentistry and Oral Medicine (166)
    • Dermatology (101)
    • Emergency Medicine (257)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (404)
    • Epidemiology (8744)
    • Forensic Medicine (4)
    • Gastroenterology (403)
    • Genetic and Genomic Medicine (1844)
    • Geriatric Medicine (175)
    • Health Economics (386)
    • Health Informatics (1281)
    • Health Policy (642)
    • Health Systems and Quality Improvement (488)
    • Hematology (206)
    • HIV/AIDS (387)
    • Infectious Diseases (except HIV/AIDS) (10519)
    • Intensive Care and Critical Care Medicine (564)
    • Medical Education (193)
    • Medical Ethics (52)
    • Nephrology (216)
    • Neurology (1744)
    • Nursing (100)
    • Nutrition (264)
    • Obstetrics and Gynecology (342)
    • Occupational and Environmental Health (457)
    • Oncology (959)
    • Ophthalmology (279)
    • Orthopedics (107)
    • Otolaryngology (174)
    • Pain Medicine (117)
    • Palliative Medicine (41)
    • Pathology (262)
    • Pediatrics (553)
    • Pharmacology and Therapeutics (264)
    • Primary Care Research (218)
    • Psychiatry and Clinical Psychology (1836)
    • Public and Global Health (3962)
    • Radiology and Imaging (649)
    • Rehabilitation Medicine and Physical Therapy (340)
    • Respiratory Medicine (532)
    • Rheumatology (214)
    • Sexual and Reproductive Health (178)
    • Sports Medicine (165)
    • Surgery (196)
    • Toxicology (37)
    • Transplantation (105)
    • Urology (78)